GSK to Acquire Experimental Blood Cancer Therapy From Chimagen in $750 Million Deal
Yahoo · 15 de sept de 2026
GSK (GSK) agreed to acquire global rights to an experimental T-cell engager therapy for multiple mye
CEDEAR LLY
Eli Lilly and Company
Sí, existe CEDEAR de LLY en Argentina. Operás bajo el ticker LLY en BYMA, con ratio 56:1 respecto a la acción en NYSE.
Empresa subyacente
HealthcareDrug Manufacturers - General
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
- País
- United States
- Empleados
- 50.000
- Sitio web
- lilly.com
Precio histórico
Últimos 203 días · 12/11/25 — 14/09/26
+21.87%
Cotización y datos
NYSERatio 56:1 · Subyacente LLY
CEDEAR (ARS)
Precio
$ 32.540
Var. %
+0,24%
Volumen operado
7.247
Subyacente (USD)
Precio LLY
US$ 1.145,36
Teórico (precio / ratio)
LLY ÷ 56
US$ 20,45
Dólar MEP (LLYD)
Preguntas frecuentes
¿Existe CEDEAR de LLY en Argentina?
Sí, existe el CEDEAR de LLY (Eli Lilly and Company) en la Bolsa de Comercio de Buenos Aires (BYMA). Su ticker local es LLY.
¿Cuál es el ticker del CEDEAR de Eli Lilly and Company?
El ticker del CEDEAR de Eli Lilly and Company en Argentina es LLY. La acción subyacente cotiza en NYSE con el símbolo LLY.
¿Cuál es el ratio del CEDEAR LLY?
El CEDEAR LLY tiene un ratio de 56:1. Eso significa que 56 CEDEARs equivalen a 1 acción de LLY.
¿Cuánto vale el CEDEAR LLY hoy?
El CEDEAR LLY cotiza hoy a $ 32.540 en pesos argentinos, con una variación diaria de +0,24%.
¿Cuánto vale la acción LLY en dólares?
La acción subyacente LLY (Eli Lilly and Company) cotiza a US$ 1.145,36 en su mercado de origen (NYSE).
Noticias
Lilly to present new data on Foundayo, retatrutide, and eloraTZP at EASD 2026, as it strives to change the course of cardiometabolic health
Yahoo · 15 de sept de 2026
Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide), Mounjaro (tirzepatide) and Foundayo (orforglipron), will present new data across its car…
QurCan Therapeutics Enters Strategic Research and Collaboration Agreement with Lilly to Advance Nucleic Acid Therapies for Central and Peripheral Nervous System Diseases
Yahoo · 15 de sept de 2026
TORONTO, September 15, 2026--QurCan Therapeutics ("QurCan"), a biotechnology company pioneering non-viral, polymer-lipid nanoparticle (PLNP) delivery of genetic…